MGCD0103 (Mocetinostat)

Catalog No. A10586

MGCD0103 (Mocetinostat) is a benzamide histone deacetylase inhibitor by inhibiting mainly histone deacetylase 1 (HDAC1), but also HDAC2, HDAC3, and HDAC11.
  • Mari Ishigami-Yuasa, .et al. Class IIb HDAC Inhibition Enhances the Inhibitory Effect of Am80, a Synthetic Retinoid, in Prostate Cancer, Biol Pharm Bull, 2019, 42, 448-452
  • Guang Bai, .et al. Chapter 1 - Epigenetic Tools in Chronic Pain Studies, Epigenetics of Chronic Pain, 2019, Pages 1-48
Catalog Num A10586
M. Wt 396.4
Formula C23H20N6O
Purity >98%
Storage at -20°C 3 years Powder
CAS No. 726169-73-9
Synonyms MGCD-0103
SMILES C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC3=NC=CC(=N3)C4=CN=CC=C4
MGCD0103 (Mocetinostat) is a benzamide histone deacetylase inhibitor by inhibiting mainly histone deacetylase 1 (HDAC1), but also HDAC2, HDAC3, and HDAC11.
Targets
Target Value
HDAC1IC50: 0.15μM
HDAC2IC50: 0.29μM
HDAC11IC50: 0.59μM
HDAC3IC50: 1.66μM
HDAC4IC50: >10μM
HDAC5IC50: >10μM
HDAC6IC50: >10μM
HDAC7IC50: >10μM
HDAC8IC50: >10μM
In vitro (25°C) DMSO 13 mg/mL (32.79 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 30% PEG400/0.5% Tween80/5% propylene glycol 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.1 mM 25.23 mL 126.14 mL 252.27 mL
0.5 mM 5.05 mL 25.23 mL 50.45 mL
1 mM 2.52 mL 12.61 mL 25.23 mL
5 mM 0.5 mL 2.52 mL 5.05 mL

*The above data is based on the productmolecular weight 396.4 . Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.